Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells

BACKGROUND: Curative treatments for patients with metastatic synovial sarcoma (SS) do not exist, and such patients have a poor prognosis. We explored combinations of molecularly-targeted and cytotoxic agents to identify synergistic treatment combinations in SS cells. METHODS: Two SS cell lines (HS-S...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Sherif S, Cranmer, Lee D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247709/
https://www.ncbi.nlm.nih.gov/pubmed/25406429
http://dx.doi.org/10.1186/1756-0500-7-812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247709/
https://www.ncbi.nlm.nih.gov/pubmed/25406429
http://dx.doi.org/10.1186/1756-0500-7-812

Ejemplares similares